The PKCθ pathway participates in the aberrant accumulation of Fra-1 protein in invasive ER-negative breast cancer cells

Oncogene

Volumn 31, Issue 47, 2012, Pages 4889-4897

  Belguise, K ^a,b,c   Milord, S ^a,b,c   Galtier, F ^a,b,c   Moquet Torcy, G ^d   Piechaczyk, M ^d   Chalbos, D ^a,b,c  

^a INSTITUT DE RECHERCHE EN CANCÉROLOGIE DE MONTPELLIER   (France)

^b UNIV MONTPELLIER   (France)

^c CENTRE VAL D AURELLE   (France)

^d CNRS   (France)

Author keywords

breast cancer cells; Fra 1; phosphorylation; PKC ; protein stability

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PHOSPHOTRANSFERASE; PROTEIN KINASE C THETA; SERINE; STE20 RELATED PROLINE ALANINE RICH KINASE; THREONINE; TRANSCRIPTION FACTOR FRA 1; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER CELL; CANCER CELL CULTURE; CELL INVASION; CELL MIGRATION; CONTROLLED STUDY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; INTRACELLULAR SIGNALING; INVASIVE ESTROGEN RECEPTOR NEGATIVE BREAST CANCER; MUTATIONAL ANALYSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RNA INTERFERENCE; UPREGULATION;

BREAST NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; FEMALE; HUMANS; ISOENZYMES; MAP KINASE SIGNALING SYSTEM; PHOSPHORYLATION; PROTEIN KINASE C; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEIN STABILITY; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS C-FOS; RECEPTORS, ESTROGEN;

EID: 84870066326     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2011.659     Document Type: Article

References (45)

1. Shaulian E, Karin M. AP-1 in cell proliferation and survival. Oncogene 2001; 20: 2390-2400. (Pubitemid 32531297)
2. Eferl R, Wagner EF. AP-1: A double-edged sword in tumorigenesis. Nat Rev Cancer 2003; 3: 859-868. (Pubitemid 37383716)
3. Young MR, Colburn NH. Fra-1 a target for cancer prevention or intervention. Gene 2006; 379: 1-11. (Pubitemid 44247331)
4. Verde P, Casalino L, Talotta F, Yaniv M, Weitzman JB. Deciphering AP-1 function in tumorigenesis: Fra-ternizing on target promoters. Cell Cycle 2007; 6: 2633-2639. (Pubitemid 350224046)
5. Mechta F, Lallemand D, Pfarr CM, Yaniv M. Transformation by ras modifies AP1 composition and activity. Oncogene 1997; 14: 837-847. (Pubitemid 27100028)
6. Vallone D, Battista S, Pierantoni GM, Fedele M, Casalino L, Santoro M et al. Neoplastic transformation of rat thyroid cells requires the junB and fra-1 gene induction which is dependent on the HMGI-C gene product. EMBO J 1997; 16: 5310-5321. (Pubitemid 27380139)
7. Kustikova O, Kramerov D, Grigorian M, Berezin V, Bock E, Lukanidin E et al. Fra-1 induces morphological transformation and increases in vitro invasiveness and motility of epithelioid adenocarcinoma cells. Mol Cell Biol 1998; 18: 7095-7105. (Pubitemid 28533029)
8. Risse-Hackl G, Adamkiewicz J, Wimmel A, Schuermann M. Transition from SCLC to NSCLC phenotype is accompanied by an increased TRE-binding activity and recruitment of specific AP-1 proteins. Oncogene 1998; 16: 3057-3068. (Pubitemid 28297728)
9. Belguise K, Kersual N, Galtier F, Chalbos D. FRA-1 expression level regulates proliferation and invasiveness of breast cancer cells. Oncogene 2005; 24: 1434-1444. (Pubitemid 40343123)
10. Vial E, Sahai E, Marshall CJ. ERK-MAPK signalling coordinately regulates activity of Rac1 and RhoA for tumor cell motility. Cancer Cell 2003; 4: 67-79. (Pubitemid 36904162)
11. Debinski W, Gibo DM. Fos-related antigen 1 modulates malignant features of glioma cells. Mol Cancer Res 2005; 3: 237-249. (Pubitemid 40525334)
12. Sayan AE, Stanford R, Vickery R, Grigorenko E, Diesch J, Kulbicki K et al. Fra-1 controls motility of bladder cancer cells via transcriptional upregulation of the receptor tyrosine kinase AXL. Oncogene 2012; 31: 1493-1503.
13. Philips A, Teyssier C, Galtier F, Rivier-Covas C, Rey JM, Rochefort H et al. FRA-1 expression level modulates regulation of activator protein-1 activity by estradiol in breast cancer cells. Mol Endocrinol 1998; 12: 973-985. (Pubitemid 30660665)
14. Milde-Langosch K, Kappes H, Riethdorf S, Loning T, Bamberger AM. FosB is highly expressed in normal mammary epithelia, but down-regulated in poorly differentiated breast carcinomas. Breast Cancer Res Treat 2003; 77: 265-275. (Pubitemid 36197641)
15. Song Y, Song S, Zhang D, Zhang Y, Chen L, Qian L et al. An association of a simultaneous nuclear and cytoplasmic localization of Fra-1 with breast malignancy. BMC Cancer 2006; 6: 298-304.
16. Chiappetta G, Ferraro A, Botti G, Monaco M, Pasquinelli R, Vuttariello E et al. FRA-1 protein overexpression is a feature of hyperplastic and neoplastic breast disorders. BMC Cancer 2007; 7: 17-28.
17. Logullo AF, Stiepcich MM, Osorio CA, Nonogaki S, Pasini FS, Rocha RM et al. Role of Fos-related antigen 1 in the progression and prognosis of ductal breast carcinoma. Histopathology 2011; 58: 617-625.
18. Wang Q, Ni H, Lan L, Wei X, Xiang R, Wang Y. Fra-1 protooncogene regulates IL-6 expression in macrophages and promotes the generation of M2d macrophages. Cell Res 2010; 20: 701-712.
19. Casalino L, De Cesare D, Verde P. Accumulation of Fra-1 in ras-transformed cells depends on both transcriptional autoregulation and MEK-dependent posttranslational stabilisation. Mol Cell Biol 2003; 23: 4401-4415. (Pubitemid 36666439)
20. Vial E, Marshall CJ. Elevated ERK-MAP kinase activity protects the FOS family member FRA-1 against proteasomal degradation in colon carcinoma cells. J Cell Sci 2003; 116: 4957-4963. (Pubitemid 38016702)
21. Basbous J, Chalbos D, Hipskind R, Jariel-Encontre I, Piechaczyk M. Ubiquitinindependent proteasomal degradation of Fra-1 is antagonized by Erk1/2 pathway-mediated phosphorylation of a unique C-terminal destabiliser. Mol Cell Biol 2007; 27: 3936-3950. (Pubitemid 47010992)
22. Harris TJ, McCormick F. The molecular pathology of cancer. Nat Rev Clin Oncol 2010; 7: 251-265.
23. Hayashi K, Altman A. Protein kinase C theta (PKCtheta): A key player in T cell life and death. Pharmacol Res 2007; 55: 537-544. (Pubitemid 46962308)
24. Marsland BJ, Kopf M. T-cell fate and function: PKC-theta and beyond. Trends Immunol 2008; 29: 179-185.
25. Blay P, Astudillo A, Buesa JM, Campo E, Abad M, Garcia-Garcia J et al. Protein kinase C theta is highly expressed in gastrointestinal stromal tumors but not in other mesenchymal neoplasias. Clin Cancer Res 2004; 10: 4089-4095. (Pubitemid 38812487)
26. Belguise K, Sonenshein GE. PKCtheta promotes c-Rel-driven mammary tumorigenesis in mice and humans by repressing estrogen receptor alpha synthesis. J Clin Invest 2007; 117: 4009-4021. (Pubitemid 350224110)
27. Wang Y, Klijn JG, Zhang Y, Sieuwerts AM, Look MP, Yang F et al. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 2005; 365: 671-679. (Pubitemid 40260888)
28. Li Y, Hu J, Vita R, Sun B, Tabata H, Altman A. SPAK kinase is a substrate and target of PKCtheta in T-cell receptor-induced AP-1 activation pathway. EMBO J 2004; 23: 1112-1122. (Pubitemid 38436875)
29. Hollestelle A, Elstrodt F, Nagel JH, Kallemeijn WW, Schutte M. Phosphatidylinositol-3-OH kinase or RAS pathway mutations in human breast cancer cell lines. Mol Cancer Res 2007; 5: 195-201. (Pubitemid 46424000)
30. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S et al. Mutations of the BRAF gene in human cancer. Nature 2002; 417: 949-954. (Pubitemid 34716871)
31. Delpire E, Gagnon KB. Genome-wide analysis of SPAK/OSR1 binding motifs. Physiol Genomics 2007; 28: 223-231. (Pubitemid 46702009)
32. Piechotta K, Lu J, Delpire E. Cation chloride cotransporters interact with the stress-related kinases Ste20-related proline-alanine-rich kinase (SPAK) and oxidative stress response 1 (OSR1). J Biol Chem 2002; 277: 50812-50819. (Pubitemid 36042246)
33. Polek TC, Talpaz M, Spivak-Kroizman T. The TNF receptor, RELT, binds SPAK and uses it to mediate p38 and JNK activation. Biochem Biophys Res Commun 2006; 343: 125-134.
34. Manicassamy S, Gupta S, Sun Z. Selective function of PKC-theta in T cells. Cell Mol Immunol 2006; 3: 263-270.
35. Chuang HC, Lan JL, Chen DY, Yang CY, Chen YM, Li JP et al. The kinase GLK controls autoimmunity and NF-jB signaling by activating the kinase PKC-y in T cells. Nat Immunol 2011; 12: 1113-1118.
36. Elsberger B, Fullerton R, Zino S, Jordan F, Mitchell TJ, Brunton VG et al. Breast cancer patients' clinical outcome measures are associated with Src kinase family member expression. Br J Cancer 2010; 103: 899-909.
37. Maurer M, Su T, Saal LH, Koujak S, Hopkins BD, Barkley CR et al. 3-Phosphoinositide-dependent kinase 1 potentiates upstream lesions on the phosphatidylinositol 3-kinase pathway in breast carcinoma. Cancer Res 2009; 69: 6299-6306.
38. Wang X, Belguise K, Kersual N, Kirsch KH, Mineva ND, Galtier F et al. Oestrogen signalling inhibits invasive phenotype by repressing RelB and its target BCL2. Nat Cell Biol 2007; 9: 470-478. (Pubitemid 46511081)
39. Chen H, Zhu G, Li Y, Padia RN, Dong Z, Pan ZK et al. Extracellular signal-regulated kinase signalling pathway regulates breast cancer cell migration by maintaining slug expression. Cancer Res 2009; 69: 9228-9235.
40. Shin S, Dimitri CA, Yoon SO, Dowdle W, Blenis J. ERK2 but not ERK1 induces epithelial-to-mesenchymal transformation via DEF motif-dependent signalling events. Mol Cell 2010; 38: 114-127.
41. Stinson S, Lackner MR, Adai AT, Yu N, Kim HJ, O'Brien C et al. TRPS1 Targeting by miR-221/222 Promotes the Epithelial-to-Mesenchymal Transition in Breast Cancer. Sci Signal 2011; 4: Ra41.
42. Doehn U, Hauge C, Frank SR, Jensen CJ, Duda K, Nielsen JV et al. RSK is a principal effector of the RAS-ERK pathway for eliciting a coordinate promotile/ invasive gene program and phenotype in epithelial cells. Mol Cell 2009; 35: 511-522.
43. Baier-Bitterlich G, Uberall F, Bauer B, Fresser F, Wachter H, Grunicke H et al. Protein kinase C-theta isoenzyme selective stimulation of the transcription factor complex AP-1 in T lymphocytes. Mol Cell Biol 1996; 16: 1842-1850.
44. Brunet A, Pages G, Pouyssegur J. Constitutively active mutants of MAP kinase kinase (MEK1) induce growth factor-relaxation and oncogenicity when expressed in fibroblasts. Oncogene 1994; 9: 3379-3387. (Pubitemid 24338470)
45. Mulloy R, Salinas S, Philips A, Hipskind RA. Activation of cyclin D1 expression by the ERK5 cascade. Oncogene 2003; 22: 5387-5398. (Pubitemid 37072193)